Cargando…

TENS Improves Cisplatin-Induced Neuropathy in Lung Cancer Patients

Background: Cisplatin-induced peripheral neuropathy is a common complication of cisplatin therapy, which develops in most patients with lung cancer. There are no effective preventive measures and once it occurs there is no effective therapy, except symptomatic. In this study, we aimed to assess the...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomanovic Vujadinovic, Sanja, Ilic, Nela, Selakovic, Ivan, Nedeljkovic, Una, Krstic, Nevena, Mujovic, Natasa, Dubljanin Raspopovic, Emilija, Jovanovic, Dragana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611034/
https://www.ncbi.nlm.nih.gov/pubmed/36295566
http://dx.doi.org/10.3390/medicina58101405
_version_ 1784819426316517376
author Tomanovic Vujadinovic, Sanja
Ilic, Nela
Selakovic, Ivan
Nedeljkovic, Una
Krstic, Nevena
Mujovic, Natasa
Dubljanin Raspopovic, Emilija
Jovanovic, Dragana
author_facet Tomanovic Vujadinovic, Sanja
Ilic, Nela
Selakovic, Ivan
Nedeljkovic, Una
Krstic, Nevena
Mujovic, Natasa
Dubljanin Raspopovic, Emilija
Jovanovic, Dragana
author_sort Tomanovic Vujadinovic, Sanja
collection PubMed
description Background: Cisplatin-induced peripheral neuropathy is a common complication of cisplatin therapy, which develops in most patients with lung cancer. There are no effective preventive measures and once it occurs there is no effective therapy, except symptomatic. In this study, we aimed to assess the effect of transcutaneous electrical nerve stimulation (TENS) therapy on the pain intensity and the quality of life of patients with cisplatin-induced neuropathy. Material and Methods: A prospective cohort study was performed from 2013 to 2018, at the Clinical Center of Serbia. After the initial evaluation of 106 newly diagnosed patients with lung cancer, 68 patients did not have peripheral neuropathy. These 68 patients continued in the study and started the cisplatin chemotherapy. Forty of these patients developed cisplatin-induced neuropathy, which was manifested by neuropathic symptoms and proven by ENG examination. All patients with cisplatin-induced neuropathy were treated with TENS therapy. Their neuropathic pain and quality of life were evaluated using the following questionnaires at diagnosis, after cisplatin therapy and after four weeks of TENS use: DN4, VAS scale, EORTC QLQ-C30 and FACT-L. Results: Two thirds (68%) of the patients with cisplatin-induced neuropathy were male and the majority were smokers (70%). Adenocarcinoma was the most common (38%), followed by squamous (33%) and small-cell carcinoma (28%). The application of TENS therapy had a positive effect on reducing the neuropathic pain and increasing the quality of life for patients with painful cisplatin-induced neuropathy. The VAS and DN4 scores significantly decreased after TENS therapy, in comparison to its values after cisplatin therapy (p < 0.001). After TENS therapy, patients had significantly higher values in most of the domains of EORTC QLQ-C30 and FACT- L, in comparison with the values after cisplatin therapy (p < 0.001). Conclusion: The application of TENS therapy has a positive effect on reducing neuropathic pain and increasing the quality of life for patients with lung cancer and cisplatin-induced neuropathy.
format Online
Article
Text
id pubmed-9611034
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96110342022-10-28 TENS Improves Cisplatin-Induced Neuropathy in Lung Cancer Patients Tomanovic Vujadinovic, Sanja Ilic, Nela Selakovic, Ivan Nedeljkovic, Una Krstic, Nevena Mujovic, Natasa Dubljanin Raspopovic, Emilija Jovanovic, Dragana Medicina (Kaunas) Article Background: Cisplatin-induced peripheral neuropathy is a common complication of cisplatin therapy, which develops in most patients with lung cancer. There are no effective preventive measures and once it occurs there is no effective therapy, except symptomatic. In this study, we aimed to assess the effect of transcutaneous electrical nerve stimulation (TENS) therapy on the pain intensity and the quality of life of patients with cisplatin-induced neuropathy. Material and Methods: A prospective cohort study was performed from 2013 to 2018, at the Clinical Center of Serbia. After the initial evaluation of 106 newly diagnosed patients with lung cancer, 68 patients did not have peripheral neuropathy. These 68 patients continued in the study and started the cisplatin chemotherapy. Forty of these patients developed cisplatin-induced neuropathy, which was manifested by neuropathic symptoms and proven by ENG examination. All patients with cisplatin-induced neuropathy were treated with TENS therapy. Their neuropathic pain and quality of life were evaluated using the following questionnaires at diagnosis, after cisplatin therapy and after four weeks of TENS use: DN4, VAS scale, EORTC QLQ-C30 and FACT-L. Results: Two thirds (68%) of the patients with cisplatin-induced neuropathy were male and the majority were smokers (70%). Adenocarcinoma was the most common (38%), followed by squamous (33%) and small-cell carcinoma (28%). The application of TENS therapy had a positive effect on reducing the neuropathic pain and increasing the quality of life for patients with painful cisplatin-induced neuropathy. The VAS and DN4 scores significantly decreased after TENS therapy, in comparison to its values after cisplatin therapy (p < 0.001). After TENS therapy, patients had significantly higher values in most of the domains of EORTC QLQ-C30 and FACT- L, in comparison with the values after cisplatin therapy (p < 0.001). Conclusion: The application of TENS therapy has a positive effect on reducing neuropathic pain and increasing the quality of life for patients with lung cancer and cisplatin-induced neuropathy. MDPI 2022-10-06 /pmc/articles/PMC9611034/ /pubmed/36295566 http://dx.doi.org/10.3390/medicina58101405 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tomanovic Vujadinovic, Sanja
Ilic, Nela
Selakovic, Ivan
Nedeljkovic, Una
Krstic, Nevena
Mujovic, Natasa
Dubljanin Raspopovic, Emilija
Jovanovic, Dragana
TENS Improves Cisplatin-Induced Neuropathy in Lung Cancer Patients
title TENS Improves Cisplatin-Induced Neuropathy in Lung Cancer Patients
title_full TENS Improves Cisplatin-Induced Neuropathy in Lung Cancer Patients
title_fullStr TENS Improves Cisplatin-Induced Neuropathy in Lung Cancer Patients
title_full_unstemmed TENS Improves Cisplatin-Induced Neuropathy in Lung Cancer Patients
title_short TENS Improves Cisplatin-Induced Neuropathy in Lung Cancer Patients
title_sort tens improves cisplatin-induced neuropathy in lung cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611034/
https://www.ncbi.nlm.nih.gov/pubmed/36295566
http://dx.doi.org/10.3390/medicina58101405
work_keys_str_mv AT tomanovicvujadinovicsanja tensimprovescisplatininducedneuropathyinlungcancerpatients
AT ilicnela tensimprovescisplatininducedneuropathyinlungcancerpatients
AT selakovicivan tensimprovescisplatininducedneuropathyinlungcancerpatients
AT nedeljkovicuna tensimprovescisplatininducedneuropathyinlungcancerpatients
AT krsticnevena tensimprovescisplatininducedneuropathyinlungcancerpatients
AT mujovicnatasa tensimprovescisplatininducedneuropathyinlungcancerpatients
AT dubljaninraspopovicemilija tensimprovescisplatininducedneuropathyinlungcancerpatients
AT jovanovicdragana tensimprovescisplatininducedneuropathyinlungcancerpatients